Local treatment of tumors
by slow-release anti-cancer drugs

About US

Intragel is a science-based company engaged in developing an innovative, state-of-the-art treatment for solid tumors based on an intra-tumoral injectable delivery system with extended release of anticancer drugs.

Intragel led by a team of highly professional and experienced scientists and business executives operates within the NGT VC in Nazareth in northern Israel.

The Need

Innovative solutions to promote life-changing therapies for head and neck cancer patients
Intragel-for_Head-and-neck-cancer
Intragel’s first product addresses an unmet need of head and neck cancer, which is the sixth most common cancer in Europe, with 250,000 cases per year. The disease afflicts  approximately 50,000 people per year in the US as well.

About 50% of these patients cannot receive chemotherapy, the standard of care, for a variety of reasons and, therefore, in the majority of cases, inevitably face death. Intragel’s treatment is designed for those cases.

Technology

Intragel’s novel technology features a pre-filled syringe which is ready to be injected into the tumor. The syringe contains an  anti-cancer drug formulated into a de-novo gel-like, hydrophobic, biocompatible and biodegradable polymer that slowly releases the drug into the tumor over a few weeks with minimal systemic toxicity.

Intragel’s technology can be applied to a wide range  of anti-cancer drugs and is suitable for various types of tumors.

Intragel’s technology is protected by a patent application.

Intragel has so-far achieved excellent pre-clinical results.

Team

DR. Peter Siman

DR. Peter Siman

CEO & Co-Founder

Brings vast experience in project management and R&D in a wide range of chemistry based medical devices.

Holds a B.Sc and M.Sc in chemistry from the Hebrew University, PhD from Ben-Gurion University in Israel and conducted his post-doctorate at the University of California, Berkeley, USA.

Prof. Avi Domb

Prof. Avi Domb

Co-Founder

As an inventor of a dozen approved products Avi brings vast experience in pharmaceutical development and innovation.

Holds a PhD in chemistry and undergraduate degrees in chemistry, pharmaceutics, and law.

Avner Geva

Avner Geva

Co-Founder

Brings experience as a seasoned entrepreneur with more than ten years in the Israeli Medtech/Pharma industry.

Previously founded and served as CEO of Vensica Therapeutics, where Avner led large, strategic and successful funding rounds.

Has a background in premedical studies and molecular biology (B.Sc, Yale) and BioMedical Engineering (M.Sc. Technion).

Zohar Gendler

Zohar Gendler

Chairman of the Board

CEO and Managing Partner of NGT3 VC. Led the establishment of and investment in more than 50 companies such as Prolor Biotech (sold to OPKO for $480M), Mazor Robotics (sold to Medtronic for $1.6B), ReWalk (NASDAQ: RWLK), Corindus (sold to Siemens Healthcare for $1.1B), and many others.

Dr. Amir Toren

Dr. Amir Toren

CTO

Holds a Ph.D in Biochemistry and Microbiology from the Department of Molecular Microbiology and Biotechnology, Tel Aviv University. Spanning a career of over fifteen years, Amir brings extensive experience from the pharmaceutical industry in managing and developing the skills and capabilities of multidisciplinary teams.

Nizar Mashal

Nizar Mashal

CFO

Manages the finances of NGT portfolio companies with strong, proven leadership.

Involved in fund-raising, negotiations and complex transactions.

Scientific Adviser

Prof. Aron Popovtzer

Prof. Aron Popovtzer

MD

Head of Sharett institute of Oncology.

Specialist in ENT, Medical and Radiation Oncology.

INTRAGEL THERAPEUTICS

Nazareth Industrial Area
Wadi El Haj 13
P.O.Box 1252 Nazareth, 17111
Israel
    Share This